Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), in collaboration with Medincell (MEDCL.PA), announced that the U.S. Food and Drug Administration has approved UZEDY (risperidone) extended-release injectable suspension for subcutaneous use. The approval covers its use as monotherapy or as adjunctive therapy alongside lithium or valproate for the maintenance treatment of bipolar I disorder in adults.
Previously approved for adult schizophrenia, UZEDY is administered once every one or two months. It is the first subcutaneous, long-acting risperidone formulation to utilize Medincell's proprietary SteadyTeq copolymer technology, which enables controlled and steady drug release. Therapeutic blood levels are achieved within 6 to 24 hours following a single dose. For bipolar I disorder, UZEDY is now available in three once-monthly dosing strengths: 50 mg, 75 mg, and 100 mg.
UZEDY was approved in the U.S. for the treatment of schizophrenia in adults in 2023.
TEVA closed Friday's regular trading at $20.03 down $0.01 or 0.05%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.